Clinical trial
Phase II Study of Cetuximab as Monotherapy and First Line Treatment in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Expressing EGFR.
NCT00240682 is registered in ClinicalTrials.gov with Centre Hospitalier of Chartres as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Cetuximab as Monotherapy and First Line Treatment in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Expressing EGFR.
- Lead sponsor
- Centre Hospitalier of Chartres
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2005
- Completion date
- June 30, 2009
- Enrollment
- 37 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.